

**Amendments to the Claims:**

The following listing of claims will replace all prior versions and listings of claims in the application and reflects cancellation of withdrawn claims 6-14.

**Listing of Claims:**

Claims 1-14 (cancelled).

Claim 15 (currently amended): An ~~A~~-immunogenic composition comprising a recombinant HIV-1 envelope protein comprising a mutated V3 loop, wherein the mutated V3 loop lacks all of the V3 loop except the GPGRAPH (SEQ ID NO: 1) hexamer sequence flanked by the two basal cysteines, and at least one pharmaceutically acceptable vehicle.

Claim 16 (previously presented): The immunogenic composition of claim 15 further comprising at least one compound selected from the group consisting of :

- (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminum hydroxide or calcium phosphate, and muramylpeptide derivatives and
- (2) liposomes.

Claim 17 (previously presented): The immunogenic composition of claim 15 wherein the envelope protein is anchored onto unilamellar synthetic lipid vesicles.

Claim 18 (previously presented): The immunogenic composition of claim 17 wherein the vesicles comprise a molar ratio of phosphatidylcholine to cholesterol of about 8:1, and which have a size of between 70 and 150 nm.

Claim 19 (previously presented): The immunogenic composition of claim 18 wherein the size of the vesicles is about 90 nm.

Claim 20 (previously presented): The immunogenic composition of claim 15 formulated for a general or systemic administration.

Claim 21 (previously presented): The immunogenic composition of claim 20, wherein said composition is formulated for oral administration.

Claim 22 (previously presented): The immunogenic composition of claim 20, wherein said composition is formulated for a local administration which involves a direct contact with a mucous membrane.

Claim 23 (previously presented): The immunogenic composition of claim 15, wherein the envelope protein is selected from the group consisting of gp160 and gp120 Env proteins.